EE-CMab 2by2 ADC is a novel dual-targeting, dual-payload bispecific antibody-drug conjugate. By simultaneously recognizing EphA2 and EGFR, it precisely delivers MMAE and Exatecan. Combining tumor-selective targeting with multi-mechanistic cytotoxicity, this platform provides a breakthrough strategy to overcome tumor heterogeneity and drug resistance in cancer therapy.

EE-CMab 2by2 ADC overcomes the limitations of traditional single-target, single-payload ADCs by integrating EphA2/EGFR dual-targeting with MMAE/Exatecan dual-payloads. This innovative architecture enables broader tumor coverage, enhanced antibody internalization, and multi-mechanistic cytotoxicity, providing a superior strategy to address tumor heterogeneity and therapeutic resistance.

EE-CMab 2by2 ADC addresses tumor heterogeneity and drug resistance through its innovative dual-targeting (EphA2/EGFR) and dual-payload (MMAE/Exatecan) architecture. This modular platform enhances therapeutic coverage and multi-mechanistic cytotoxicity. With strong First-in-class potential, it is optimized for global out-licensing and commercialization, positioning it as a leader in the next-generation precision oncology market.